AstraZeneca Covid-19 vaccine shows promise - report
15th Jul 2020 11:42
(Sharecast News) - A Covid-19 vaccine backed by AstraZeneca is producing positive results in initial trials, according to a report.
Read moreOxford Biomedica swings to loss as licensing revenue falls
6th May 2020 12:52
(Sharecast News) - Gene and cell therapy company Oxford Biomedica reported an improvement in bioprocessing and commercial development revenues to ?47.3m in its preliminary results on Wednesday, from ?40.5m.
Read moreLiberum hikes target price on Oxford Biomedica
28th Apr 2020 11:13
(Sharecast News) - Analysts at Liberum hiked their target price on gene and cell therapy company Oxford BioMedica from £8.60 per share to £10.90 on Tuesday, citing demand at its new OxBox manufacturing facility.
Read moreOxford Biomedica joins Covid-19 vaccine consortium
8th Apr 2020 16:13
(Sharecast News) - Gene and cell therapy company Oxford Biomedica has joined a consortium led by the Jenner Institute at Oxford University, it announced on Wednesday, to rapidly develop, scale-up and manufacture a potential vaccine candidate for Covid-19, called 'ChAdOx1 nCov-19'.
Read moreNovo Holdings pours ?53.5m into Oxford Biomedica
28th May 2019 13:18
(Sharecast News) - Gene and cell therapy company Oxford Biomedica announced on Tuesday that Novo Holdings has agreed to invest up to £53.5m in the group, in return for new ordinary shares representing up to 10.1% of the outstanding shares after the capital increase.
Read moreFriday broker round-up
15th Mar 2019 12:46
(Sharecast News) - Bakkavor Group: Berenberg downgrades to sell with a target price of 105p.
Read moreOxford Biomedica swings to positive earnings in 2018
14th Mar 2019 14:16
(Sharecast News) - Gene and cell therapy group Oxford Biomedica reported a 72% increase in gross income in its preliminary results for the year ended 31 December on Thursday, to £67.9m.
Read moreOxford Biomedica enters research collaboration with Microsoft
12th Mar 2019 10:10
(Sharecast News) - Gene and cell therapy company Oxford Biomedica has entered into a research and development collaboration with Microsoft Research, it announced on Tuesday, to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning.
Read moreOxford BioMedica forms new digital framework initiative
23rd Nov 2018 10:59
(Sharecast News) - Gene and cell therapy group Oxford BioMedica announced the formation of a new digital framework initiative on Friday, which it said would streamline the production of next-generation medicines.
Read moreFirst patient successfully dosed with Oxford BioMedica's OXB-102
25th Oct 2018 10:14
(Sharecast News) - Gene and cell therapy group Oxford BioMedica noted on Thursday that its partner, Axovant Sciences - a company developing innovative gene therapies for neurologic and neuromuscular diseases - has announced the successful dosing of the first patient in a clinical study of AXO-Lenti-PD, also known as OXB-102.
Read more'Transformative year' sees Oxford Biomedica profit from two huge contracts
13th Sep 2018 15:46
(Sharecast News) - Biopharmaceutical company Oxford Biomedica saw its shares rise on Thursday after its first half gross income more than doubled due to two huge contracts.
Read moreOxford BioMedica's RetinoStat achieves 'favourable safety profile' in tests
10th Oct 2016 14:19
(ShareCast News) - AIM-listed pharmaceutical Oxford BioMedica's RetinoStat, the first ocular lentiviral gene therapy to be administered in humans, demonstrated a "favourable safety profile with no serious adverse events" in its phase one study. Results of the study, which were previously published i
Read moreOxford Biomedica to raise £8.1m in placing
23rd Feb 2016 12:23
(ShareCast News) - Biopharmaceutical company Oxford Biomedica plans to raise £8.1m in a placing of 128.4m shares at 6.3p with new and existing investors. The placing, which is priced at a 10% discount to the 7p closing price on 22 February, is to provide adequate working capital for the group to con
Read moreOxford Biomedica signs 'transformational' new contract with Novartis
3rd Nov 2014 11:43
Gene and cell therapy company Oxford Biomedica has signed a 'transformational' new contract with Novartis worth up to $90m over the next three years. The group will pay $14m upfront, including a $4.3m equity subscription for a non-exclusive worldwide development and commercialisation licence in onco
Read moreFriday broker round-up UPDATE
10th Oct 2014 09:42
British American Tobacco: Goldman Sachs reduces target price from 3530p to 3250p downgrading to sell. Brown (N) Group: UBS cuts target price from 490p to 445p leaving its buy recommendation unchanged. Diageo: Goldman Sachs reduces target price from 2030p to 1925p and keeps a neutral rating. Dixons
Read more